Related Experiment Videos
Advances in gastrointestinal pharmacotherapy
David C Metz1, Nimish Vakil, Emmet B Keeffe
1Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Summary
Advances in gastrointestinal disease management include new antisecretory therapies, improved treatments for chronic hepatitis C (HCV) nonresponders, and promising immunomodulators for inflammatory bowel disease.
Area of Science:
- Gastroenterology
- Hepatology
- Immunology
Background:
- Medical management of gastrointestinal diseases is rapidly evolving.
- A 2005 symposium focused on future prospects for antisecretory therapy, chronic hepatitis C, and inflammatory bowel disease.
Purpose of the Study:
- To review advancements in the medical management of key gastrointestinal diseases.
- To highlight emerging therapeutic strategies and their potential impact.
Main Methods:
- Discussion of antisecretory drug combinations (proton pump inhibitors, potassium-competitive acid blockers, antigastrin agents).
- Review of treatment regimens for chronic hepatitis C, focusing on nonresponders.
- Exploration of immunomodulators and biologics for inflammatory bowel disease.
Main Results:
- Antisecretory combinations show potential to enhance existing therapies.
- Peginterferon with ribavirin offers improved sustained virologic response rates in prior nonresponders to hepatitis C treatment.
- Newer strategies for hepatitis C eradication and anti-TNFalpha agents for inflammatory bowel disease show promise.
Conclusions:
- Future gastrointestinal disease management will benefit from novel drug combinations and targeted therapies.
- Further evaluation of risk-benefit ratios and costs is needed for some emerging treatments.
- Biologics represent a significant advancement in treating inflammatory bowel disease.